BioMarin’s Voxzogo has been shown to increase growth rates in children with hypochondroplasia, a genetic cause of very short stature, in a phase 2 trial. Hypochondroplasia is a form of skeletal ...

BioMarin Pharmaceutical (Nasdaq: BMRN) reported $747.31 million in revenue for the fourth quarter, a 16% year-over-year increase. The San Rafael-based global producer of genetic treatments for ...

If you’re on the fence about investing in argenx SE or BioMarin Pharmaceutical Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a biotechnology company specializing in therapies for rare genetic diseases with a market capitalization of $13.15 billion, has been navigating a ...

BioMarin Pharmaceutical stock opened at $68.25 on Thursday. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. The firm has a 50-day moving average ...

Robert W. Baird lowered their target price on BioMarin Pharmaceutical from $72.00 to $65.00 and set a “neutral” rating on the stock in a report on Wednesday, October 30th.

A slimmed-down BioMarin started the new year with a bang, hitting the annual J.P. Morgan Healthcare Conference with the goal of tapping its skillset to strike deals that bolster its pipeline of ...

Both headline numbers obliterated analyst estimates. Collectively, pundits tracking BioMarin's stock were estimating the company would earn a bit over $711 million and post an adjusted net income ...

Alexander Hardy; President, Chief Executive Officer, Director; Biomarin Pharmaceutical Inc Brian Mueller; Chief Financial Officer, Executive Vice President; Biomarin Pharmaceutical Inc Cristin ...